91915:TYSABRI ANTIBODIES

Print View Attached Docs:
91915:TYSABRI ANTIBODIES
Alias Names: Natalizumab
Methodology: Enzyme-Linked Immunosorbent Assay (ELISA)
Edit Date: 10/26/2009
Performed: Monday
Released: 1-8 days after setup at PeaceHealth Laboratories’ reference lab.
CPT Code: 83516-90
Specimen Collection Details
Collection: One 7.5 mL serum separator tube (SST).
Handling: Allow to clot, centrifuge and separate serum from cells and pour into a plastic vial.
Stability: 7 days ambient, 14 days refrigerated, or 30 days frozen.
Standard Volume: 1 mL serum
Minimum Volume: 0.5 mL serum
Transport: Refrigerated.
Comments: Tysabri® is a monoclonal antibody therapy used to treat patients with relapsing forms of multiple sclerosis (MS), a serious autoimmune disease that results in damage to the brain and spinal cord. Tysabri® (natalizumab) binds to proteins called alpha-4-integrins, which are found primarily on the surface of white blood cells, and play a role in immune system acitvity. Patients being treated with Tysabri® can develop Tysabri-specific antibodies that may block the therapeutic effect of the treatment. This assay detects antibodies that bind to Tysabri® in vitro; a positive result should not be interpreted as definitive evidence of in vivo blocking activity.

Reference Range:
Negative Antibodies not detected
Positive Antibodies detected
This assay detects antibodies that bind to Tysabri® in vitro; a positive result should not be interpreted as definitive evidence of in vivo blocking activity.

Family Medicine for America's Health